3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Research

• Publication date

  2002-06-15

• Fields of study

  Medicine

• Identifiers
  PMID 12067968
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.

  2001cited by this paper
• (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.

  2001cited by this paper
• A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis.

  2001cited by this paper
• F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma

  2001cited by this paper
• Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?

  2001cited by this paper
• Simplified Labeling Approach for Synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT)

  2000cited by this paper
• FDG PET measurement of the proliferative potential of non-small cell lung cancer.

  2000cited by this paper
• Molecular biologic substaging of stage I lung cancer according to gender and histology.

  2000cited by this paper
• Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography.

  2000cited by this paper
• Lung nodule enhancement at CT: multicenter study.

  2000cited by this paper
• Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.

  2000cited by this paper
• Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.

  1999cited by this paper
• Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group.

  1999cited by this paper
• Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants.

  1999cited by this paper
• Imaging proliferation in vivo with [F-18]FLT and positron emission tomography

  1998cited by this paper
• Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.

  1997cited by this paper
• Prognostic issues in non-small cell lung cancer.

  1995cited by this paper
• Improved iterative image reconstruction using variable projection binning and abbreviated convolution

  1994cited by this paper
• Regulation of human thymidine kinase during the cell cycle.

  1988cited by this paper

• Hypoxia Imaging in Lung Cancer: A PET-Based Narrative Review for Clinicians and Researchers

  2025cites this paper
• Radiomic analysis will add differential diagnostic value of benign and malignant pulmonary nodules: a hybrid imaging study based on [18F]FDG and [18F]FLT PET/CT

  2023cites this paper
• PET tracers in glioblastoma: Toward neurotheranostics as an individualized medicine approach

  2023cites this paper
• A Role of Non-FDG Tracers in Lung Cancer?

  2022cites this paper
• New PET Tracers: Current Knowledge and Perspectives in Lung Cancer.

  2022cites this paper
• Clinical value of 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer

  2021cites this paper
• Liver background uptake of [18F]FLT in PET imaging.

  2020cites this paper
• Tumour Biology Characterisation by Imaging in Clinic

  2020cites this paper
• Non-FDG PET/CT.

  2020cites this paper
• A review on immunohistochemical and histopathologic validation in PET-CT findings with consideration to microRNAs

  2019cites this paper
• The role of new PET tracers for lung cancer

  2019cites this paper
• Dual time point [18F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues

  2019cites this paper
• PET in Neuro-Oncology

  2019cites this paper
• PET imaging in glioma: techniques and current evidence

  2018cites this paper
• Folate receptor‐targeted 19F MR molecular imaging and proliferation evaluation of lung cancer

  2018cites this paper
• Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis

  2018cites this paper
• Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment.

  2018cites this paper
• Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Diagnosis and Staging of Lung Cancer

  2018cites this paper
• Relative skeletal distribution of proliferating marrow in the adult dog determined using 3′‐deoxy‐3′‐[18F]fluorothymidine

  2018cites this paper
• Noninvasive quantification of F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma

  2017cites this paper
• Instructions for use Title Assessment of early changes in H-3-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression

  2017cites this paper
• Evolution of lymphoma staging and response evaluation: current limitations and future directions

  2017cites this paper
• The Positron Emission Tomography Tracer 3’-Deoxy-3’-[18F]Fluorothymidine ([18F]FLT) Is Not Suitable to Detect Tissue Proliferation Induced by Systemic Yersinia enterocolitica Infection in Mice

  2016cites this paper
• Positron Emission Tomography.

  2016cites this paper
• eview he role of new PET tracers for lung cancer

  2016cites this paper
• Dynamic PET evaluation of elevated FLT level after sorafenib treatment in mice bearing human renal cell carcinoma xenograft

  2016cites this paper
• Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents: 18F-FAU, 18F-FMAU, and 18F-FLT

  2016cites this paper
• Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma

  2016cites this paper
• The role of new PET tracers for lung cancer.

  2016cites this paper
• Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics

  2016cites this paper
• Imaging Anti-Proliferative Compounds With Flt-Pet

  2016cites this paper
• Review Article Monitoring of anti-cancer treatment with 18 F-FDG and 18 F-FLT PET: a comprehensive review of pre-clinical studies

  2015cites this paper
• 18F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study

  2015cites this paper
• In vivo imaging of therapy response to a novel Pan-HER antibody mixture using FDG and FLT positron emission tomography

  2015cites this paper
• Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies.

  2015cites this paper
• Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies.

  2015cites this paper
• Prognostic Value Comparison Between 18F-FLT PET/CT and 18F-FDG PET/CT Volume-Based Metabolic Parameters in Patients with Head and Neck Cancer

  2015cites this paper
• Developing biomarker-specific end points in lung cancer clinical trials

  2015cites this paper
• Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer

  2015cites this paper
• Comparison of the diagnostic performance of 18F-fluorothymidine versus 18F-fluorodeoxyglucose positron emission tomography on pulmonary lesions: A meta analysis.

  2015cites this paper
• Multimodal Image-Guided Surgical and Photodynamic Interventions in Head and Neck Cancer: From Primary Tumor to Metastatic Drainage

  2015cites this paper
• Fast and efficient microscale radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine

  2014cites this paper
• PET Tracers in Musculoskeletal Disease beyond FDG

  2014cites this paper
• Positron Emission Tomography with [18F]FLT Revealed Sevoflurane-Induced Inhibition of Neural Progenitor Cell Expansion in vivo

  2014cites this paper
• In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET

  2014cites this paper
• Physiologic Uptake, Variants, and Pitfalls

  2014cites this paper
• Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

  2014cites this paper
• Imaging of molecular target modulation in oncology: challenges of early clinical trials

  2014cites this paper
• Apport de l'imagerie médicale fonctionnelle dans le diagnostic du nodule pulmonaire

  2014cites this paper
• Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls.

  2014cites this paper
• Development of (18)F-labeled PET probes for imaging cell proliferation.

  2013cites this paper
• Imaging of Treatment Response to the Combination of Carboplatin and Paclitaxel in Human Ovarian Cancer Xenograft Tumors in Mice Using FDG and FLT PET

  2013cites this paper
• Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.

  2013cites this paper
• 3′-Deoxy-3′-[18F]-fluorothymidine ([18F]-FLT) transport in newly diagnosed glioma: correlation with nucleoside transporter expression, vascularization, and blood–brain barrier permeability

  2013cites this paper
• Molecular imaging in oncology.

  2013cites this paper
• [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice

  2013cites this paper
• Design, Synthesis and Development of Transporter Targeting Agents for Image-guided Therapy and Drug Delivery

  2013cites this paper
• The role of F-18-fluorothymidine PET in oncology

  2013cites this paper
• An optical proteomic profile of the HER2 family in breast tumours and the effect of exposure to tyrosine kinase inhibitors

  2013cites this paper
• The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice

  2013cites this paper
• Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib

  2013cites this paper
• 18F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome

  2013cites this paper
• ⁹⁹mTc-N4amG: synthesis biodistribution and imaging in breast tumor-bearing rodents.

  2013cites this paper
• Limits of [18F]-FLT PET as a Biomarker of Proliferation in Oncology

  2013cites this paper
• Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.

  2013cites this paper
• Molecular imaging for characterization of lymphoma biology and monitoring response to cancer drug therapy

  2013cites this paper
• Positron Emission Tomography-Based Molecular Imaging

  2012cites this paper
• New PET radiopharmaceuticals beyond FDG for brain tumor imaging.

  2012cites this paper
• Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non--small-cell lung cancer.

  2012cites this paper
• Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis.

  2012cites this paper
• Characterization of transport of positron emission tomography tracer 3′-deoxy-3′-fluorothymidine by nucleoside transporters

  2012cites this paper
• Radiosynthesis of 3′‐Deoxy‐3′‐[18F]Fluorothymidine ([18F]FLT)

  2012cites this paper
• Structural and Molecular Imaging in Cancer Therapy Clinical Trials

  2012cites this paper
• [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment.

  2012cites this paper
• Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis.

  2012cites this paper
• Levels of human equilibrative nucleoside transporter-1 are higher in proliferating regions of A549 tumor cells grown as tumor xenografts in vivo.

  2012cites this paper
• Positron Emission Tomography Imaging of Platinum Resistant Ovarian Cancer And Drug Modulation

  2012cites this paper
• Applications of Positron Emission Tomography in the Development of Molecular Targeted Cancer Therapeutics

  2012cites this paper
• Imaging proliferation of 18F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer

  2012cites this paper
• 3′‐deoxy‐3′‐[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma

  2012cites this paper
• Molecular imaging in cancer treatment

  2011cites this paper
• Microwave-assisted one-pot radiosynthesis of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-d-arabinofuranosyluracil ([18F]-FMAU).

  2011cites this paper
• [18F]FLT PET for Non-Invasive Monitoring of Early Response to Gene Therapy in Experimental Gliomas

  2011cites this paper
• PET/CT Imaging

  2011cites this paper
• Molecular imaging for the quantitative assessment of tumor proliferation, progression and the early assessment of molecular targeted treatment response

  2011cites this paper
• Imaging of lung cancer in the era of molecular medicine.

  2011cites this paper
• Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3'deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging.

  2011cites this paper
• Improved synthesis of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil ([18F]FMAU).

  2011cites this paper
• Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

  2011cites this paper
• Application of positron emission tomography molecular probes in hepatocellular carcinoma biological imaging.

  2011cites this paper
• Imaging with non-FDG PET tracers: outlook for current clinical applications

  2010cites this paper
• Molecular imaging using positron emission tomography in gastrointestinal malignancy

  2010cites this paper
• Fully automated and simplified radiosynthesis of [18F]-3′-deoxy-3′-fluorothymidine using anhydro precursor and single neutral alumina column purification

  2010cites this paper
• Early response assessment in prostate carcinoma by 18F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models

  2010cites this paper
• Alternative PET Tracers in Musculoskeletal Disease.

  2010cites this paper
• PET in the diagnosis and management of patients with brain metastasis: Current role and future perspectives

  2010cites this paper
• PET/CT with 18F-FLT Is Unlikely to Cause Significant Hepatorenal or Hematologic Toxicity

  2010cites this paper
• PET-CT for response assessment and treatment adaptation in head and neck cancer.

  2010cites this paper
• PET/CT in cancer research: from preclinical to clinical applications.

  2010cites this paper
• The Role of Molecular Imaging in Evaluating Tumor Response to Targeted Radiotherapy

  2010cites this paper